Global AIDS group calls on Boehringer ingelheim to increase access to drugs
This article was originally published in Scrip
The AIDS Healthcare Foundation (AHF) is accusing Boehringer Ingelheim of steadfastly refusing to offer increased access to its lifesaving AIDS drugs or to respond in any way to repeated requests to do its part in helping alleviate a current crisis facing low-income Americans. Tom Myers, AHF's chief of public affairs and general counsel, says that many AIDS drug makers are making an effort to make access easier by expediting their own patient assistance programmes, although this hasn't fully happened yet. But the advocacy group claims that Boehringer is an "outlier" even among this group.
You may also be interested in...
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.